Frank Neumann, Kite global head of clinical development
ASH: Gilead's CAR-T Yescarta holds up in more first-line lymphoma patients as part of earlier use push
With the cell therapy field largely pivoting to the next generation of those drugs, established players like Gilead’s Kite and Bristol Myers Squibb are still …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
